Virbac Stock Approaches Its €370 Resistance Two Days Before Earnings Release
Virbac is trading at €367.50 this Tuesday during the session, up 2.23% from the previous close. The veterinary laboratory's stock, which has accumulated a gain of nearly 25.5% over the year, is approaching the announcement of its quarterly revenue in two days.
In mid-afternoon, Virbac is priced at €367.50, very close to its identified resistance at €370. The price now slightly exceeds the upper boundary of the Bollinger Bands (€367.40), which could indicate a potential overbought signal: the stock is beyond 100% of the band's amplitude, a situation that may precede a reversion to the mean. However, the RSI at 58 does not yet indicate extreme tension, remaining in a balanced zone. The short-term dynamics are favorable: the price is above both its 50-day moving average (€353.40) and 200-day moving average (€344.89), reflecting a well-established upward trend. Over the past seven days, the gain reached 4.7%. The stock's ability to sustainably break through the €370 threshold will be a critical point to watch to confirm the continuation of this movement or a possible pullback to the €328.50 support level.
Financial Calendar as a Key Factor
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The financial calendar is a key factor for the upcoming sessions: Virbac will publish its first-quarter 2026 revenue on April 16, just two days away. This imminent deadline may help explain the increased activity on the stock this Tuesday. The general assembly is scheduled for June 26, followed by the half-year results expected on September 17. In a supportive market environment — the CAC 40 is up 0.79% in the session, the SBF 120 by 0.83% — Virbac outperforms the Paris indices. It is noteworthy that in the healthcare sector, Sanofi is up by 1.17% while UCB is down by 0.18%. The particularly low beta of the stock (0.07) indicates a very limited correlation with the overall market, as Virbac operates under dynamics largely specific to the animal health sector. On the American side, healthcare stocks to watch in the same sector include Lilly (Eli), Johnson & Johnson, and AbbVie.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 1 168 millions d'euros
Quarterly revenue: 1 168 millions d'euros
Guidance from the release
Notre solide performance à fin septembre 2026 nous permet de viser le haut de notre fourchette initiale de croissance du chiffre d'affaires
Risks mentioned
Effets de change défavorables impactant la croissance réelle (croissance réelle +5,9% vs +7,9% à taux constants)
Pression concurrentielle persistante sur les vaccins porcins en Asie de l'Est et pressions tarifaires au segment Animaux d'élevage
Exposition au Moyen-Orient et suivi des tendances inflationnistes (énergie) malgré anticipation d'impacts limités
Opportunities identified
Croissance soutenue des plateformes Supercharge (+11% environ) couvrant petfood, reproduction, dentaire, mobilité, otologie, endocrinologie et ruminants
Intégration fluide de Thyronorm dans la franchise d'endocrinologie avec contribution de +1 point de croissance et +0,5 point d'Ebit ajusté
Redémarrage réussi de la production du contrat majeur de façonnage en Amérique du Nord (juillet 2026) après contrainte réglementaire temporaire
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: « Bien que nos perspectives pour l'ensemble de l'année 2026 restent inchangées, notre solide performance à fin septembre (croissance de +7,9%) nous permet de viser la borne haute de notre fourchette de croissance du chiffre d'affaires de 5,5 % à 7,5 % à PCC »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
